{"id":540523,"date":"2021-04-26T19:28:01","date_gmt":"2021-04-26T19:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540523"},"modified":"2021-04-26T19:28:01","modified_gmt":"2021-04-26T19:28:01","slug":"myasthenia-gravis-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-pipeline-assessment-key-companies-and-emerging-drugs_540523.html","title":{"rendered":"Myasthenia Gravis Pipeline Assessment, Key Companies, And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myasthenia Gravis Pipeline Assessment, Key Companies, And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Myasthenia Gravis Pipeline Assessment, Key Companies, And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Myasthenia Gravis Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis Market. <\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The <strong>Myasthenia Gravis Pipeline<\/strong><\/span><span data-mce-mark=\"1\"><strong> report<\/strong> embraces in-depth <\/span><span data-mce-mark=\"1\">commercial <\/span><span data-mce-mark=\"1\">and clinical assessment of the Myasthenia Gravis pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span><strong><span data-mce-mark=\"1\">Myasthenia Gravis collaborations<\/span><\/strong><span data-mce-mark=\"1\">, mergers, acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Myasthenia Gravis Pipeline is crowded with several potential therapies as many companies are working robustly on developing many new therapies for MG.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Myasthenia Gravis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/5926d0141c38e1393ad33837f8fa7b4b.jpg\" alt=\"Myasthenia Gravis Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Companies:<\/strong><br \/>Takeda<br \/>Argenx<br \/>Immunovant<br \/>UCB Pharma<br \/>CSL Behring<br \/>Ra Pharmaceuticals<br \/>Alexion Pharmaceuticals<br \/>Momenta Pharmaceuticals<br \/>Catalyst Pharmaceuticals<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Therapies covered in the report include:<\/strong><br \/>Firdapse<br \/>Hizentra <br \/>Rozanolixizumab <br \/>Efgartigimod<br \/>Zilucoplan <br \/>Ravulizumab <br \/>IMVT-1401 <br \/>M281<br \/>TAK-079 <br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Myasthenia Gravis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the <\/span><span data-mce-mark=\"1\"><strong>treatment of Myasthenia Gravis<\/strong> <\/span><span data-mce-mark=\"1\">with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Myasthenia Gravis Treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Myasthenia Gravis key companies <\/span><\/strong><span data-mce-mark=\"1\">involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Myasthenia Gravis Drugs<\/span><span data-mce-mark=\"1\"> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the <\/span><strong><span data-mce-mark=\"1\">Myasthenia Gravis market<\/span><\/strong><span data-mce-mark=\"1\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The <\/span><strong><span data-mce-mark=\"1\">Myasthenia Gravis Pipeline Report<\/span><\/strong><span data-mce-mark=\"1\"> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and<\/span><span data-mce-mark=\"1\"> MOA type for Myasthenia Gravis <\/span><span data-mce-mark=\"1\">across the complete product development cycle, including all clinical and non-clinical stages.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It comprises detailed profiles of <\/span><strong><span data-mce-mark=\"1\">Myasthenia Gravis therapeutic products<\/span><\/strong><span data-mce-mark=\"1\"> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed research and development progress and<\/span><span data-mce-mark=\"1\"> clinical trial of Myasthenia Gravis<\/span><span data-mce-mark=\"1\">, results wherever available, are also included in the pipeline study.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across <strong>Myasthenia Gravis<\/strong>.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A better understanding of disease pathogenesis contributing to the development of <\/span><strong><span data-mce-mark=\"1\">novel therapeutics for Myasthenia Gravis<\/span><\/strong><span data-mce-mark=\"1\">.&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the <strong>Myasthenia Gravis market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics are working to assess challenges and seek opportunities that could influence <\/span><span data-mce-mark=\"1\">Myasthenia Gravis Research &amp; Development<\/span><span data-mce-mark=\"1\">. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong><span data-mce-mark=\"1\">Myasthenia Gravis treatment market<\/span><\/strong><\/a><span data-mce-mark=\"1\">. Several potential therapies for Myasthenia Gravis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Myasthenia Gravis market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the <\/span><strong><span data-mce-mark=\"1\">Myasthenia Gravis pipeline<\/span><\/strong><span data-mce-mark=\"1\"><strong> assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Myasthenia Gravis&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Myasthenia Gravis Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Myasthenia Gravis &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Myasthenia Gravis Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Myasthenia Gravis Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Myasthenia Gravis Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Myasthenia Gravis Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Myasthenia Gravis Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Myasthenia Gravis Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. Myasthenia Gravis Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Myasthenia Gravis Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. Myasthenia Gravis Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Myasthenia Gravis Market Insight<br \/><\/a><\/strong>DelveInsight&#8217;s &#8220;Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as Myasthenia Gravis market size, share, and trend analysis for the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\"><strong>Healthcare Blogs &#8211;&nbsp;<br \/>Sinusitis Disease and Treatment Options<br \/><\/strong>For the treatment of Sinus infections, avoidance of the triggers is mostly effective. However, as not all allergens are avoidable, companies such as GeneOne Life Science, Lyra Therapeutics, Optinose, AnaptysBio, Argenx, Medtronic, Merck, Sanofi, Pfizer, Precigen, ProclaRx LLC, Quorum Innovations, Regeneron and others are working to develop therapies in the Sinusitis market to address the allergy sinus pain.<strong> For more details, visit: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/sinusitis-disease-overview\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Sinusitis Signs, Symptoms and Treatments<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myasthenia-gravis-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myasthenia-gravis-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Myasthenia Gravis Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis Market. The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-pipeline-assessment-key-companies-and-emerging-drugs_540523.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-540523","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540523"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540523\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}